Yinghua Lang

3.6k total citations · 1 hit paper
15 papers, 1.4k citations indexed

About

Yinghua Lang is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Yinghua Lang has authored 15 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Epidemiology and 5 papers in Surgery. Recurrent topics in Yinghua Lang's work include Inflammatory Bowel Disease (14 papers), Microscopic Colitis (9 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Yinghua Lang is often cited by papers focused on Inflammatory Bowel Disease (14 papers), Microscopic Colitis (9 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Yinghua Lang collaborates with scholars based in United States, Canada and Belgium. Yinghua Lang's co-authors include William J. Sandborn, Brian G. Feagan, Paul Rutgeerts, Jean‐Frédéric Colombel, Colleen Marano, Bruce E. Sands, Gary R. Lichtenstein, Daniel H. Present, Stephen B. Hanauer and Walter Reinisch and has published in prestigious journals such as Gastroenterology, Gut and The American Journal of Gastroenterology.

In The Last Decade

Yinghua Lang

15 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

2011 693 citations Jean‐Frédéric Colombel, Paul Rutgeerts et al. Gastroenterology profile →

Peers

Countries citing papers authored by Yinghua Lang

Since Specialization

Citations

This map shows the geographic impact of Yinghua Lang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yinghua Lang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yinghua Lang more than expected).

Fields of papers citing papers by Yinghua Lang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yinghua Lang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yinghua Lang. The network helps show where Yinghua Lang may publish in the future.

Co-authorship network of co-authors of Yinghua Lang

This figure shows the co-authorship network connecting the top 25 collaborators of Yinghua Lang. A scholar is included among the top collaborators of Yinghua Lang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yinghua Lang. Yinghua Lang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease 2018 ·Gastroenterology ·Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Jean‐Frédéric Colombel, Douglas C. Wolf, (unknown), Jewel Johanns, Philippe Szapary, Omoniyi J. Adedokun, Brian G. Feagan, William J. Sandborn	115
2	The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn’s Disease 2018 ·Journal of Crohn s and Colitis ·Bruce E. Sands, Chenglong Han, Christopher Gasink, (unknown), Philippe Szapary, (unknown), Yinghua Lang, Stephan R. Targan, William J. Sandborn, Brian G. Feagan	23
3	Endoscopic Healing in Induction and Maintenance with Ustekinumab in the Phase 3 UNITI Crohnʼs Disease Program: 2016 ACG Presidential Poster Award 2016 ·The American Journal of Gastroenterology ·William J. Sandborn, C Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Stephen B. Hanauer, Douglas C. Wolf, (unknown), Jewel Johanns, Philippe Szapary, Brian Feagan, Paul Rutgeerts	2
4	OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn’s Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2 2016 ·(unknown), Christopher Gasink, Yinghua Lang, (unknown), Jewel Johanns, (unknown), Bruce E. Sands, S. B. Hanauer, P. Rutgeerts, Stephan R. Targan, Subrata Ghosh, (unknown), J F Colombel, Zsolt Tulassay, Ursula Seidler, WJ Sandborn	2
5	O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα 2016 ·Inflammatory Bowel Diseases ·William J. Sandborn, Christopher Gasink, Marion Blank, Yinghua Lang, Jewel Johanns, Long-Long Gao, Bruce E. Sands, Stephen B. Hanauer, Brian G. Feagan, Stephan R. Targan, Subrata Ghosh, (unknown), Jean–Frédéric Colombel, Scott Lee, Pierre Desreumaux, Edward V. Loftus, Séverine Vermeire, Paul Rutgeerts	38
6	OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn’s Disease (CD) Refractory to anti-TNFΑ: UNITI-1 2016 ·Gut ·P. Rutgeerts, Christopher Gasink, (unknown), Yinghua Lang, Jewel Johanns, (unknown), Bruce E. Sands, S. B. Hanauer, (unknown), Stephan R. Targan, Subrata Ghosh, (unknown), J F Colombel, Shin‐Da Lee, Pierre Desreumaux, Edward V. Loftus, Séverine Vermeire, WJ Sandborn	2
7	Tu2006 Ustekinumab Improves General Health Status and Disease-Specific Health Related Quality of Life of Patients with Moderate to Severe Crohn's Disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials 2016 ·Gastroenterology ·Bruce E. Sands, Chenglong Han, Christopher Gasink, Philippe Szapary, Long-Long Gao, Yinghua Lang, Brian G. Feagan	10
8	Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis breakdown → 2011 ·Gastroenterology ·Jean‐Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, Dirk Eßer, Yanxin Wang, Yinghua Lang, Colleen Marano, Richard Strauß, B.J. Oddens, Brian G. Feagan, Stephen B. Hanauer, Gary R. Lichtenstein, Daniel H. Present, Bruce E. Sands, William J. Sandborn	693
9	Long-term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT-1 and -2 Extension Studies 2011 ·Inflammatory Bowel Diseases ·Walter Reinisch, William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Marion Blank, Yinghua Lang, Jewel Johanns, Jean‐Frédéric Colombel, Daniel H. Present, Bruce E. Sands	164
10	Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension 2011 ·Current Medical Research and Opinion ·Jeffrey S. Hyams, Thomas D. Walters, Wallace Crandall, Subra Kugathasan, Anne M. Griffiths, Marion Blank, Jewel Johanns, Yinghua Lang, James Markowitz, Stanley A. Cohen, Harland S. Winter, G. Veereman‐Wauters, George D. Ferry, Robert N. Baldassano	79
11	A post-hoc analysis 2011 ·Inflammatory Bowel Diseases ·(unknown), Paul Rutgeerts, Walter Reinisch, Diederik Esser, (unknown), Yinghua Lang, Colleen Marano, Richard E. Strauss, B.J. Oddens, Brian Feagan, Stephen B. Hanauer, Gary Lichtenstein, (unknown), B E Sands, Jean‐Frédéric Colombel	6
12	Mucosal Healing in Patients with Ulcerative Colitis Associates with a Reduced Colectomy Risk, High Incidence of Symptomatic Remission, and Corticosteroid-Free State 2010 ·The American Journal of Gastroenterology ·William J. Sandborn, Paul Rutgeerts, Walter Reinisch, Dirk Eßer, (unknown), Yinghua Lang, Colleen Marano, Richard Strauss, B.J. Oddens, Brian Feagan, Stephen B. Hanauer, Gary R. Lichtenstein, Daniel H. Present, Bruce E. Sands, Jean–Frédéric Colombel	7
13	Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials 2009 ·Alimentary Pharmacology & Therapeutics ·Gary Lichtenstein, Robert H. Diamond, Carrie Wagner, Adedigbo A. Fasanmade, A. Olson, Colleen Marano, Jewel Johanns, Yinghua Lang, William J. Sandborn	162
14	Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease 2009 ·The American Journal of Gastroenterology ·Gary Toedter, Marion Blank, Yinghua Lang, Dion Chen, William J. Sandborn, Willem J.S. de Villiers	53
15	T1139 The ACT Trials: Incremental Benefit of Second and Third Induction Doses of Infliximab in Patients with Moderately-to-Severely Active Ulcerative Colitis (UC) 2008 ·Gastroenterology ·William J. Sandborn, Paul Rutgeerts, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Yinghua Lang, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J. de Villiers, Daniel H. Present, Bruce E. Sands, Jean‐Frédéric Colombel	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact